Drugs / Roluperidone
Roluperidone
also known as
MIN-101 · CYR-101 · CYR-101 HYDROCHLORIDE DIHYDRATE · MIN-101 FREE BASE · MR-32 · MT-210 · Roluperidona · ROLUPERIDONE HYDROCHLORIDE
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06107803 | Oct 2023 → Jan 2024 | schizophrenia | Minerva Neurosciences | Completed | No outcome recorded |
| Phase 1 | NCT03072056 | Jan → Jul 2017 | — | Minerva Neurosciences | Completed | No outcome recorded |
| Phase 1 | NCT03038646 | Nov 2016 → Apr 2017 | — | Minerva Neurosciences | Completed | No outcome recorded |
| Phase 1 | NCT02232529 | Sep 2014 → Feb 2015 | schizophrenia | Minerva Neurosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00861796 | Mar 2008 → May 2010 | schizophrenia | Cyrenaic Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07565428 | Apr 2026 → Dec 2027 expected | — | Minerva Neurosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03397134 | Dec 2017 → May 2020 | — | Minerva Neurosciences | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Roluperidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07565428 ↗ |
| Known as | CYR-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00861796 ↗ |
| Known as | CYR-101 HYDROCHLORIDE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297605 ↗ |
| Known as | MIN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02232529 ↗ |
| Known as | MIN-101 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297605 ↗ |
| Known as | MR-32 | “32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state” NCT03038646 ↗ |
| Known as | MT-210 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297605 ↗ |
| Known as | Roluperidona | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297605 ↗ |
| Known as | ROLUPERIDONE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297605 ↗ |
| Action | Inhibit | “a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors” PMID 35211743 ↗ May 2022 |
| Modality | Small molecule | — CHEMBL4297605 ↗ |
| Route | Oral | “when administered orally” NCT00861796 ↗ |